General Electric’s deal to sell its Biopharma unit to Danaher might be in jeopardy, according to Gordon Haskett analyst John Inch, after several competitors posted weaker than expected results. That’s not good news for General Electric. The company expects to receive $20 billion cash from the asset sale and investors expect GE to use that cash to pay down debt with deal proceeds. Any problems with the Danaher deal would certainly mean more volatility for GE shareholders. If something does scuttle the deal, GE would likely proceed with an IPO of its entire health care business. That was the company’s original plan before Danaher emerged as a buyer for the business unit. Learn More